Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer Detailed Data to be Presented at an Upcoming Medical Congress THOUSAND OAKS, Calif. , Aug. 30, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS® (sotorasib) met its primary endpoint of progression-free survival (PFS), demonstrating statistical significance and superiority over standard of care chemotherapy, intravenous docetaxel.

AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER

Amgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

Amgen (AMGN) Outperforms Industry Year to Date: What's Next?

New Positive Data From Phase 3 SPROUT Trial, Studying Otezla (apremilast) in Children Ages 6-17 With Moderate to Severe Plaque Psoriasis Positive Results From the Phase 3 DISCREET Study, Investigating Clinical Efficacy and Safety of Otezla in Patients With Moderate to Severe Genital Psoriasis New Rocatinlimab Phase 2 Analyses Highlight Emerging Clinical Profile in Moderate to Severe Atopic Dermatitis THOUSAND OAKS, Calif. , Aug. 30, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that clinical and real-world data from across its inflammation portfolio, including both established treatments and pipeline assets, will be presented at the 31st European Academy of Dermatology and Venereology (EADV), taking place in Milan, Italy, Sept.

AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022

AbbVie

Bristol-Myers

CVS Health

Gilead Sciences

Eli Lilly

Merck

Pfizer

The stock market rally ran into the harsh reality last Friday that any interest rate pivot by the Federal Reserve may not come until 2024.

8 Safe ‘Strong Buy' Health Care Dividend Stocks to Buy as Summer Bear Market Rally Ends

Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of

NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS

Amgen is showing very low implied volatility compared to recent history. That could mean it's a good time to buy an option strangle.

Take Advantage Of Low Volatility In Amgen Stock With Options

Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.

Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study

Vanguard Health Care ETF

The healthcare sector has been under pressure for years as lawmakers have been trying to curb the escalation of pharmaceutical prices. The recent signing of the Inflation Reduction Act marks a major milestone for such efforts.

Inflation Reduction Act: VHT Should Be OK, But Amgen Can Fair Better

Study Evaluated the Efficacy, Safety and Immunogenicity of ABP 959 Compared to Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria THOUSAND OAKS, Calif. , Aug. 23, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive top-line results from the DAHLIA study, a randomized, double-blind, active-controlled, two-period crossover Phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS® (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)

Late-breaking Hot Line Oral Presentation on FOURIER-OLE Data Represents Longest Trials of a PCSK9i to Date New HEYMANS, HAUSER Data to be Presented THOUSAND OAKS, Calif. , Aug. 22, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of eight cardiovascular (CV) scientific research abstracts, including long-term and real-world evidence studies that add to the robust body of evidence demonstrating the efficacy and safety profile of Repatha® (evolocumab).

AMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® (EVOLOCUMAB) SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS

VanEck Vectors Biotech ETF

Biogen

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.

How Are Biotech ETFs Reacting to Q2 Earnings Releases?

The U.S. Senate Finance Committee is widening its investigation into the tax practices of U.S. drugmakers to include Amgen Inc, according to a letter sent on Thursday by the committee's chairman, Senator Ron Wyden.

Senate Finance Committee looks at Amgen taxes, widening drugmaker probe

Chemocentryx

Global Blood Therapeutics

Seagen

SPDR S&P Pharmaceuticals ETF

Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.

Get ready for more merger mania in pharma sector the rest of the year

Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer No Approved Treatment Options Available to Patients in Third-line Setting THOUSAND OAKS, Calif. , Aug. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the safety and efficacy of investigational tarlatamab, a potential first-in-class half-life extended bispecific T-cell engager (HLE BiTE®) molecule targeting delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022

Inovio Pharmaceuticals

Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles

Two Appealing Biotech Stocks for Two Distinct investors

Amgen has seen stagnation in recent years, as it has been pursuing M&A to bolster the pipeline and reignite growth. Deals still have to make a contribution, as stagnating sales, buybacks, deals and an IRS issue increase leverage quite a bit.

Amgen: Adding To The Pipeline

First Data From LUMAKRAS Plus Immunotherapy and LUMAKRAS Plus SHP2 Inhibitor Combinations Show Clinical Activity and Support Ongoing Investigation Updated Phase 1 Tarlatamab Data Reinforce Potential of BiTE® Therapy in Small Cell Lung Cancer THOUSAND OAKS, Calif. , Aug. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced three new data sets from its thoracic oncology portfolio that will be presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) from August 6-9 in Vienna, Austria.

AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS

Amgen (AMGN) beats Q2 estimates for earnings and sales. It offers to buy ChemoCentryx (CCXI) for $3.7 billion.

Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx

Amgen Inc. (NASDAQ:AMGN ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Arvind Sood - VP, IR Bob Bradway - Chairman and CEO Peter Griffith - CFO Murdo Gordon - EVP, Global Commercial Operations David Reese - EVP, Research and Development Conference Call Participants Jay Olson - Oppenheimer Chris Raymond - Piper Sandler Salveen Richter - Goldman Sachs Umer Raffat - Evercore ISI Michael Yee - Jefferies Matthew Harrison - Morgan Stanley David Risinger - SVB Securities Mohit Bansal - Wells Fargo Geoff Meacham - Bank of America Yaron Werber - Cowen Carter Gould - Barclays Evan Seigerman - BMO Michael Schmidt - Guggenheim Robyn Karnauskas - Truist Dane Leone - Raymond James Tim Anderson - Wolfe Research Operator My name is Jason and I'll be your conference facilitator today for Amgen's Second Quarter of 2022 Financial Results Conference Call. [Operator Instructions] I would now like to introduce Arvind Sood, Vice President of Investor Relations.

Amgen Inc. (AMGN) CEO Bob Bradway on Q2 2022 Results - Earnings Call Transcript

On Thursday, shares of ChemoCentryx Inc. ( CCXI , Financial) shot up more than 110% before closing the day at $50.43 on the news that the small-cap biotech company has entered into an agreement to be acquired by major drugmaker Amgen Inc. ( AMGN , Financial) in an all-cash deal worth $3.7 billion, or $52 per share.

ChemoCentrix Spikes 110% on Amgen Acquisition Deal

NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI), in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN).Under the terms of the merger agreement, the Company's shareholders will receive $52.00 in cash for each share of ChemoCentryx common stock owned. The transaction is valued at approximately $3.7 billion.

SHAREHOLDER ALERT: Weiss Law Investigates ChemoCentryx, Inc

Amgen narrowed its outlook for 2022 sales late Thursday after its second-quarter beat. But Amgen stock fell just a fraction.

Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx

THOUSAND OAKS, Calif. , Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022.

AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

Source: Shutterstock ChemoCentryx (NASDAQ: CCXI ) stock is rocketing higher on Thursday as investors react to news of an acquisition deal with Amgen (NASDAQ: AMGN ). This deal has Amgen agreeing to acquire ChemoCentryx for $3.7 billion in cash.

ChemoCentryx (CCXI) Stock Soars 100% on Amgen Acquisition

Amgen (AMGN) is buying ChemoCentryx (CCXI) for $4 billion in cash. These are the details.

News for Amgen Stock (AMGN)